抑制Scpep1通过改善线粒体生物能量学减轻心肌梗死诱导的心功能障碍
该研究在小鼠心肌梗死模型中评估Scpep1缺失、心脏特异性敲低及过表达对心功能的影响,发现Scpep1通过结合Pex3促其降解而损害线粒体生物能量学,加剧心肌梗死诱导的心功能障碍和损伤;药物抑制Scpep1可改善线粒体片段化和生物能量学,提示Scpep1是减轻心肌梗死的潜在治疗靶点。
要点
- 心肌梗死后循环和心脏Scpep1水平上调。
- Scpep1缺失或心脏特异性敲低减轻心肌梗死诱导的心功能障碍和损伤。
- 药物抑制Scpep1改善心肌梗死后线粒体片段化和生物能量学。
核心结论
- Scpep1缺失通过改善Pex3介导的线粒体分裂及后续心肌细胞凋亡来减轻心肌梗死。
- Scpep1是减轻心肌梗死的潜在治疗靶点。
研究设计与样本
- 在小鼠心肌梗死模型中评估Scpep1缺失、心脏特异性敲低和Scpep1过表达对心功能的影响。
- 利用蛋白质组学分析并采用功能缺失和功能获得策略确认Scpep1的下游功能介质。
主要发现
- 心肌梗死小鼠的循环和心脏Scpep1水平上调。
- Scpep1基因敲除或心脏特异性敲低减轻心肌梗死诱导的心功能障碍和损伤,而心脏特异性过表达加重这些不良效应。
- Scpep1通过结合Pex3促其降解,损害线粒体生物能量学,最终导致线粒体分裂和凋亡,从而加重心肌梗死诱导的心功能障碍和损伤。
- 心肌梗死或缺血性心肌病患者的血浆和心脏组织中Scpep1表达谱与小鼠模型一致。
- 药物抑制Scpep1通过改善心肌梗死后线粒体片段化和生物能量学,显著改善心肌梗死诱导的心功能障碍和损伤。
临床怎么用
- Scpep1可作为减轻心肌梗死的潜在治疗靶点,药物抑制Scpep1在动物模型中改善心肌梗死后心功能和线粒体损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Myocardial infarction (MI) is an ischaemic cardiovascular disease associated with increased morbidity and mortality. Previous studies have suggested that serine carboxypeptidase 1 (Scpep1) is involved in vascular diseases; however, its role in cardiac diseases remains unclear. This study aims to explore the role of Scpep1 in regulating cardiac homeostasis during MI. METHODS: The impact of Scpep1 deficiency or cardiac-specific knock-down and Scpep1 overexpression on heart function was evaluated in mice with MI. Its downstream functional mediators of Scpep1 were elucidated using proteomic analysis and confirmed by employing loss- and gain-of-function strategies. RESULTS: Circulating and cardiac Scpep1 levels were up-regulated in mice with MI. Genetic ablation or cardiac-specific knock-down of Scpep1 alleviated MI-induced cardiac dysfunction and damage in mice. In contrast, cardiac-specific Scpep1 overexpression aggravated these adverse effects. Mechanistically, Scpep1 exacerbated MI-induced cardiac dysfunction and damage by impaired mitochondrial bioenergetics via binding to Pex3 to promote its degradation, ultimately contributing to mitochondrial fission and apoptosis. Moreover, the expressional profiles of Scpep1 in plasma samples and heart tissues of patients with MI or ischaemic cardiomyopathy were in line with those observed in the mouse models. In addition, pharmaceutical inhibition of Scpep1 notably improved MI-induced cardiac dysfunction and damage by improving mitochondrial fragmentation and bioenergetics post-MI. CONCLUSIONS: Scpep1 deficiency mitigates MI by improving Pex3-mediated mitochondrial fission and subsequent cardiomyocyte apoptosis. Scpep1 constitutes a potential therapeutic target for attenuating MI.
引用
- Chen, Gan, Wu, et al. Scpep1 inhibition attenuates myocardial infarction-induced dysfunction by improving mitochondrial bioenergetics. Eur Heart J. 2025. PMID: 39932164. doi:10.1093/eurheartj/ehaf032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。